• Explore /
  • Poster
  • / Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.

Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.

Abstract Poster

Authors

Yohann Loriot

Yohann Loriot

Institut de Cancérologie Gustave Roussy, Villejuif, France

Yohann Loriot , Arjun Vasant Balar , Daniel P. Petrylak , Arash Rezazadeh , Petros Grivas , Aude Flechon , Rohit K. Jain , Neeraj Agarwal , Manojkumar Bupathi , Philippe Barthelemy , Philippe Beuzeboc , Phillip Lee Palmbos , Christos Kyriakopoulos , Damien Pouessel , Cora N. Sternberg , Julia Tonelli , Emon Elboudwarej , Lauri Diehl , Juliane Margarete Jürgensmeier , Scott T. Tagawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03547973

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4579)

DOI

10.1200/JCO.2023.41.16_suppl.4579

Abstract #

4579

Poster Bd #

71

Abstract Disclosures

Similar Posters

First Author: Natalie Rainey

First Author: Vivek Subbiah

First Author: Michal Sternschuss

First Author: Chethan Ramamurthy